THAR Tharimmune Inc: Earnings per share for the trailing year

Tharimmune, Inc. (THAR) relies critically on venture capital due to a lack of internal revenue during early-stage testing. The year-over-year EPS (TTM) history visualizes this dependency, with the current metric standing at 63.80. The company is establishing a closed scientific loop via its antibody platform and developing strategic alliances with institutions to engineer innovative anti-cancer vaccines.
Tharimmune Corporation - analytical breakdowns and key metrics (THAR)

This indicator measures the dynamics of net earnings per share over the last 12 months relative to the same period last year, allowing for an assessment of operational efficiency stability and business capitalization rates. For Tharimmune, Inc. (THAR), which combines biotechnology with blockchain finance, the annual EPS growth rate over the last 12 months reflects the company's ability to convert innovation into real income amid currency fluctuations.